Lateral Flow Immunoassay for SARS-CoV-2 Antibody Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current lateral flow immunoassays for detecting human antibodies against SARS CoV-2 face challenges in sensitivity and specificity, leading to false negative and false positive results, and are unable to accurately differentiate between infection and vaccination status.
Innovation Solution
The development of an immunoassay device with multiple capture zones for SARS CoV-2 N and S proteins, using non-human anti-human IgG and IgM antibodies, and immobilized SARS CoV-2 proteins or peptides, which requires detection at specific test lines to confirm the presence of IgG and IgM antibodies, allowing for differentiation between infection and vaccination.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional lateral flow immunoassays are used for SARS CoV-2 antibody detection, then the device simplicity is maintained, but sensitivity and specificity deteriorate leading to false negative and false positive results
Solution Approach 1:
The assay is divided into multiple independent test lines (S-test line with SARS CoV-2 spike protein and N-test line with nucleocapsid protein) that simultaneously detect different antibody types (IgG and IgM). This segmentation allows parallel detection of multiple analytes, improving reliability by requiring concordant results across multiple lines to confirm positive status and reduce false positives.
Solution Approach 2:
The assay combines multiple detection capabilities into a single lateral flow device: detection of both IgG and IgM antibodies, testing against both S and N proteins, and inclusion of control lines. This merging maintains device simplicity while enhancing detection accuracy through multi-parameter assessment in one test.
2Adaptability or versatility
If conventional lateral flow immunoassays are used, then ease of operation is maintained, but the ability to differentiate between infection and vaccination status deteriorates
Solution Approach 1:
The assay uses separate test lines for S protein and N protein detection, allowing differentiation based on antibody patterns: vaccination typically induces anti-S antibodies only, while natural infection produces both anti-S and anti-N antibodies. This segmented approach provides adaptability for distinguishing infection sources without requiring multiple separate tests.
Solution Approach 2:
The single lateral flow device performs multiple functions simultaneously: detecting IgG and IgM antibodies, testing against S and N proteins, providing control validation, and enabling infection versus vaccination differentiation. This multi-functionality achieves high adaptability while maintaining ease of operation through a unified test platform.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The device provides sensitive and specific detection of SARS CoV-2 antibodies, reducing false results and enabling differentiation between infection and vaccination status, thereby improving diagnostic accuracy.
Implementation Method 1
one or more capture zones comprising an test line comprising an immobilized SARS CoV-2 protein or peptide... a detectable reagent comprising i) any SARS CoV-2 protein or peptide... or ii) a non-human anti-human IgG, a non-human antihuman IgM antibody
Data Source
AI summary
Lateral flow immunoassays that reliably detect human antibodies, including IgG and/or IgM antibodies, specific for severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) are described herein. Devices, methods and kits for analysis of samples, such as liquid blood, serum or plasma, for the presence of human antibodies, such as IgG and/or IgM antibodies, specific for SARS CoV-2 proteins, such as SARS CoV-2 N and/or S proteins are provided.